Table 2. Validated pSNMs in the three individuals.
| Individual | ID | Position | Ref base | Alt base | Whole-genome sequencing |
Pyrosequencing |
Sanger sequening |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref read # (%) | Alt read # (%) | Ref % | Alt % | Ref clone # | Alt clone # | |||||
| ACC1-II-1 | B1 | 15:80878576 | C | T | 118 (93%) | 9 (7%) | 91% | 9% | 41 | 4 |
| ACC1-II-1 | B2 | 4:165099831 | C | T | 73 (89%) | 9 (11%) | 90% | 10% | 105 | 5 |
| ACC1-II-1 | B3 | 6:85605629 | A | T | 86 (87%) | 13 (13%) | 90% | 10% | 75 | 11 |
| ACC1-II-1 | B5 | 6:154692299 | G | C | 104 (95%) | 6 (5%) | 87% | 13% | 91 | 8 |
| ACC1-II-1 | B13 | 18:70512197 | T | G | 67 (69%) | 30 (31%) | 64% | 36% | 29 | 15 |
| DS1-II-2 | F1 | 17:52287119 | G | T | 89 (88%) | 12 (12%) | 91% | 9% | 33 | 3 |
| DS1-II-2 | F2 | 19:55529705 | C | T | 93 (93%) | 7 (7%) | 93% | 7% | 167 | 2 |
| DS1-II-2 | F3 | 19:56343191 | T | C | 86 (92%) | 7 (8%) | 96% | 4% | 82 | 4 |
| DS1-II-2 | F6 | 14:71380614 | T | G | 73 (92%) | 6 (8%) | 92% | 8% | 113 | 3 |
| DS1-II-2 | F7 | 16:84073033 | A | C | 44 (83%) | 9 (17%) | 88% | 12% | 36 | 4 |
| DS1-II-2 | F9 | 13:79932615 | C | A | 51 (73%) | 19 (27%) | 77% | 23% | 25 | 9 |
| DS1-II-2 | F10 | 2:166848782 | G | C | 38 (76%) | 12 (24%) | 73% | 27% | 19 | 3 |
| DS2-I-1 | X1 | 1:72008400 | A | G | 93 (90%) | 10 (10%) | 77% | 23% | 20 | 3 |
| DS2-I-1 | X2 | 16:64312186 | C | T | 76 (92%) | 7 (8%) | 88% | 12% | 24 | 5 |
| DS2-I-1 | X3 | X:68611473 | C | A | 47 (90%) | 5 (10%) | 94% | 6% | 166 | 3 |
| DS2-I-1 | X6 | 2:166854673 | G | T | 58 (78%) | 16 (22%) | 78% | 22% | 30 | 8 |
| DS2-I-1 | X8 | 13:89662020 | A | C | 53 (77%) | 16 (23%) | 82% | 18% | 45 | 9 |